C4 Therapeutics Inc (NASDAQ: CCCC) open the trading on Thursday, with a bit cautious approach as it glided -4.80% to $2.38, before settling in for the price of $2.5 at the close. Taking a more long-term approach, CCCC posted a 52-week range of $1.09-$5.10.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -8.92%. Meanwhile, its Annual Earning per share during the time was -8.92%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 2.66%. This publicly-traded company’s shares outstanding now amounts to $96.91 million, simultaneously with a float of $77.61 million. The organization now has a market capitalization sitting at $230.66 million. At the time of writing, stock’s 50-day Moving Average stood at $2.48, while the 200-day Moving Average is $2.13.
C4 Therapeutics Inc (CCCC) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. C4 Therapeutics Inc’s current insider ownership accounts for 19.92%, in contrast to 57.44% institutional ownership. According to the most recent insider trade that took place on Feb 18 ’25, this organization’s Chief Business Officer sold 669 shares at the rate of 3.15, making the entire transaction reach 2,107 in total value, affecting insider ownership by 107,805. Preceding that transaction, on Feb 14 ’25, Company’s Chief Business Officer sold 490 for 3.15, making the whole transaction’s value amount to 1,544. This particular insider is now the holder of 110,842 in total.
C4 Therapeutics Inc (CCCC) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.27 per share during the current fiscal year.
C4 Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 2.66% and is forecasted to reach -1.41 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 9.68% through the next 5 years, which can be compared against the -8.92% growth it accomplished over the previous five years trading on the market.
C4 Therapeutics Inc (NASDAQ: CCCC) Trading Performance Indicators
Let’s observe the current performance indicators for C4 Therapeutics Inc (CCCC). It’s Quick Ratio in the last reported quarter now stands at 5.76. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 7.66.
In the same vein, CCCC’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.67, a figure that is expected to reach -0.29 in the next quarter, and analysts are predicting that it will be -1.41 at the market close of one year from today.
Technical Analysis of C4 Therapeutics Inc (CCCC)
[C4 Therapeutics Inc, CCCC] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 62.17% While, its Average True Range was 44.23.
Raw Stochastic average of C4 Therapeutics Inc (CCCC) in the period of the previous 100 days is set at 42.79%, which indicates a major fall in contrast to 43.75% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.17 that was lower than 0.23 volatility it exhibited in the past 100-days period.
